HAVANA, Cuba, Mar 11 (ACN) The Center for State Control of Medicines, Equipment and Medical Devices (Cecmed by its Spanish acronym) granted the Conditional Sanitary Registration to Nasalferon, a nasal application solution for the prophylaxis of SARS-CoV-2 infection, the virus that causes COVID-19.
After evaluating the dossier, the Cuban regulatory entity concluded that the product, also called recombinant human lnterferon alfa 2b, meets the quality, safety and efficacy requirements, the Center for Genetic Engineering and Biotechnology (CIGB), developer of Nasalferon, informed on X.
The Conditional Health Registration is a